of inflammatory factors in synovial fibroblasts by inhibiting the PI3K/AKT pathway in a rat model of monosodium iodoacetate-induced osteoarthritis [J]. Exp Ther Med, 2018, 16(6):4737-4744.
[11] Jiang BC, Liu T, Gao YJ. Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential [J]. Pharmacol Ther, 2020, 212:107581.
[12] Kc R, Li X, Kroin JS, *et al*. PKCδ null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth [J]. Ann Rheum Dis, 2016, 75(12):2133-2141.
[13] Gowler PRW, Li L, Woodhams SG, *et al*. Peripheral brain-derived neurotrophic factor contributes to chronic osteoarthritis joint pain [J]. Pain, 2020, 161(1):61-73.
[14] Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues [J]. Semin Arthritis Rheum, 2003, 33(3):155-167.
[15] England S, Bevan S, Docherty RJ. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade [J]. J Physiol, 1996, 495(Pt 2): 429-440.
[16] Mantyh PW. Mechanisms that drive bone pain across the lifespan [J]. Br J Clin Pharmacol, 2019, 85(6): 1103-1113.
[17] Kelly S, Chapman RJ, Woodhams S, *et al*. Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain [J]. Ann Rheum Dis, 2015, 74(1):252-259.
[18] Lv Z, Xu X, Sun Z, *et al*. TRPV1 alleviates osteoarthritis by inhibiting M1 macrophage polarization via Ca(2+)/CaMKII/Nrf2 signaling pathway [J]. Cell Death Dis, 2021, 12(6):504.
[19] Gwilym SE, Keltner JR, Warnaby CE, *et al*. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients [J]. Arthritis Rheum, 2009, 61(9): 1226-1234.
[20] Kelly S, Dobson KL, Harris J. Spinal nociceptive reflexes are sensitized in the monosodium iodoacetate model of osteoarthritis pain in the rat [J]. Osteoarthritis Cartilage, 2013, 21(9):1327-1335.
[21] Sagar DR, Burston JJ, Hathway GJ, *et al*. The contribution of spinal glial cells to chronic pain behaviour in the monosodium iodoacetate model of osteoarthritic pain [J]. Mol Pain, 2011, 7:88.
[22] 宋莉 , 宋学军 . 慢性疼痛的研究模型、外周和脊髓机制及临床治疗进展 [J]. 中国疼痛医学杂志 , 2015, 21(1): 2-7.
[23] Mélik Parsadaniantz S, Rivat C, Rostène W, *et al*. Opioid and chemokine receptor crosstalk: a promising target for pain therapy?[J]. Nat Rev Neurosci, 2015, 16(2):69-78.
[24] Savvidou O, Milonaki M, Goumenos S, *et al*. Glucocorticoid signaling and osteoarthritis [J]. Mol Cell Endocrinol, 2019, 480:153-166.
[25] Xavier AM, Anunciato AK, Rosenstock TR, *et al*. Gene expression control by glucocorticoid receptors during innate immune responses[J]. Front Endocrinol, 2016, 7:31.

·消　息·

电针仪国际标准颁布

2022 年 6 月 6 日，由韩济生院士指导，韩松平教授牵头编制的《电针仪安全和基本性能要求》，顺利通过国际标准化组织 (ISO) 的评审并正式颁布，编码为 ISO 24571:2022；该标准的颁布填补了电针领域国际标准的空白。

针灸作为传统医学的重要分支，以良好的临床疗效，始终走在中医国际化发展的前列。电针仪作为现代针灸科研转化成果更是受到患者的青睐；由于相关国际标准缺失，电针的安全性和有效性一直是各国政府有关部门高度关注的焦点，而国际标准的制定牵扯到多个国家的利益。2012 年，北京大学神经科学研究所韩济生院士和韩松平教授联合韩国、日本、加拿大等国家相关研究机构向国际标准化机构申请编制电针仪国际标准；在国家中医药管理局、中国中医科学院和国家标准化管理委员会的大力支持下，历经十年，经过反复论证、研讨、多方协调，最终经世界各国政府代表投票获得全票通过。

《电针仪安全和基本性能要求》国际标准的颁布将有利于提高全球电针仪的质量，促进针刺疗法在全球范围内更加科学、安全、有效地使用，促进中医药国际贸易和中医药国际化，为全球健康贡献“中国方案”和“标准力量”。